Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 168 clinical trials
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

platinum-based chemotherapy.

gilbert's syndrome
carcinoma
liver metastasis
thymic carcinoma
renal function
  • 136 views
  • 23 Jan, 2021
  • 15 locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for

recurrent endometrial cancer
carcinoma
maintenance therapy
durvalumab
carcinosarcoma
  • 104 views
  • 31 Jan, 2021
  • 169 locations
A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Suitable for Definitive Chemoradiotherapy

The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

  • 0 views
  • 03 Feb, 2021
  • 53 locations
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer

platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

carcinoma
HER2
adjuvant therapy
triple negative breast cancer
carboplatin
  • 10 views
  • 21 Jan, 2021
  • 1 location
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

  • 0 views
  • 15 Feb, 2021
  • 75 locations
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based

cancer chemotherapy
carcinoma
peritoneal cancer
cancer antigen 125
platinum-based chemotherapy
  • 392 views
  • 10 Feb, 2021
  • 42 locations
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.

cancer of the ovary
cancer chemotherapy
fallopian tube
breast cancer
ovarian epithelial cancer
  • 0 views
  • 04 Feb, 2021
  • 63 locations
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

who are PD-1/PD-L1 inhibitor nave and have progressed on a platinum based chemotherapy regimen.

measurable disease
lung carcinoma
cancer chemotherapy
pd-1 inhibitor
  • 0 views
  • 21 Feb, 2021
  • 44 locations
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

  • 0 views
  • 01 Feb, 2021
  • 42 locations
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.

  • 65 views
  • 24 Jan, 2021
  • 107 locations